Renalytix AI Clinches £11.8M in Optimistic Fundraise

Renalytix AI (GB:RENX) has released an update.

Renalytix AI, an AI-enabled diagnostics company focusing on kidney disease, has successfully raised £11.8 million through a stock placement and subscription at a premium price, with shares issued to Mount Sinai in exchange for debt forgiveness. CEO James McCullough expresses optimism for the company’s growth potential, expecting profitability and break-even cash flow in two years and forecasting revenues of approximately $17.5 million in FY27.

For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.